Deciphera Pharmaceuticals, Inc.

Equities

DCPH

US24344T1016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 01:10:43 2024-05-21 pm EDT			5-day change	1st Jan Change
25.48 ^USD	+0.02%		+0.12%	+57.90%

May. 10	Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 01	North American Morning Briefing : Traders Wait for -2-	DJ

Deciphera Pharmaceuticals, Inc. Announces Resignation of Liam Ratcliffe from the Board of Directors

February 22, 2019 at 04:24 pm EST

On February 15, 2019, Liam Ratcliffe, M.D., Ph.D. provided Deciphera Pharmaceuticals, Inc. with notice of his resignation from the Board of Directors of the Company, effective as of February 22, 2019. Dr. Ratcliffe’s resignation was voluntary and to pursue other professional endeavors and not the result of any disagreement with the operations, policies or practices of the Company.

Latest news about Deciphera Pharmaceuticals, Inc.

Deciphera Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
North American Morning Briefing : Traders Wait for -2-	May. 01	DJ
Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	Apr. 30	MT
Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	Apr. 30	MT
JMP Downgrades Deciphera Pharmaceuticals to Market Perform	Apr. 30	MT
North American Morning Briefing : More Earnings -2-	Apr. 30	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
US Equity Markets Close Higher Monday Ahead of Earnings, Fed Meeting This Week	Apr. 29	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Apr. 29	MT
Top Midday Gainers	Apr. 29	MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	Apr. 29	MT
Deciphera Agrees to $2.4 Billion Buyout Offer From Japan's ONO Pharmaceutical	Apr. 29	MT
Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	Apr. 29	MT
Deciphera Shares Hit 2-Year High After $2.4 Billion Buyout Offer From ONO Pharma	Apr. 29	DJ
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Sector Update: Health Care	Apr. 29	MT
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Deciphera Pharmaceuticals Gets $2.4 Billion Buyout Offer From ONO Pharmaceutical	Apr. 29	DJ
Deciphera Pharmaceuticals to Be Acquired by ONO Pharmaceutical in $2.4 Billion Deal	Apr. 29	MT
Japan's Ono Pharmaceutical to buy Deciphera for $2.4 billion	Apr. 29	RE
Ono Pharmaceutical Co., Ltd. entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. for $2.2 billion.	Apr. 28	CI
Transcript : Deciphera Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 08:00 AM	Mar. 13
Deciphera Pharmaceuticals' Q4 Net Loss Narrows, Revenue Rises	Feb. 06	MT

Chart Deciphera Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.

Sector

Biotechnology & Medical Research

Calendar

2024-06-20 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Deciphera Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

25.47 USD

Average target price

26.71 USD

Spread / Average Target

+4.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DECIPHERA PHARMACEUTICALS, INC.	+57.90%	2.2B
VERTEX PHARMACEUTICALS INCORPORATED	+7.88%	115B
REGENERON PHARMACEUTICALS, INC.	+12.93%	107B
BIONTECH SE	-13.57%	22.31B
ARGENX SE	-3.99%	21.6B
BEIGENE, LTD.	-6.35%	18.23B
WUXI APPTEC CO., LTD.	-39.93%	17.62B
NEUROCRINE BIOSCIENCES, INC.	+7.09%	14.26B
SAREPTA THERAPEUTICS, INC.	+33.18%	12.37B
LEGEND BIOTECH CORPORATION	-28.07%	8.28B

Bio Therapeutic Drugs